Please login to the form below
Zarzio
This page shows the latest Zarzio news and features for those working in and with pharma, biotech and healthcare.
Clock ticking on biosimilar Enbrel in US
In markets outsider the US - where it is known as Zarzio and has been available since 2006 - Sandoz' drug has captured around a 30% share of the Neupogen market.
Latest news
-
Novartis launches first biosimilar Zarxio in the US
therapies.”. Biosimilars have been available in Europe since 2006 and Zarxio is already available in more than 40 countries under the brand name Zarzio, where it has captured around 30% of
-
Apotex latest to file Neupogen biosimilar in the US
the brand name Zarzio.
-
FDA close to first biosimilar approval
US under the brand name Zarzio.
-
Biosimilars could make EU big cost savings after slow start
In the case of Amgen's once-daily white blood cell stimulator Neupogen (filgrastim), however, the drug has now been overtaken by its biosimilar rivals - led by Sandoz' Zarzio - and the
-
FDA 'must publish biosimilar naming guide soon'
as Zarzio - in Europe in 2009. ... According to the company Zarzio is the leading G-CSF in Europe with a 30 per cent market share.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Account Director – UK Office
-
Excellent salary and benefits
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Director
-
£Competitive Salary
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Senior Account Manager
-
Salary TBC
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
- FDA grants emergency authorisation to chloroquine for COVID-19
- AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance
- Novartis donates malaria drug for COVID-19 clinical trials
- Moderna and GSK advance coronavirus vaccine candidates
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- Germany's coronavirus infections climb but deaths remain low
- OSE lung cancer vaccine clears phase 3 hurdle, but COVID-19 stalls programme
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- UK government reveals only 2,000 key NHS staff have been tested for coronavirus
- Today’s reality: how to make social distancing work in medcomms
- Q&A: Kate Paxton
- Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
- Pharma funding and M&A in 2020
- Why pharma M&A has continually bucked the trend...
- Behaviour change through medical education: How can we turn aspiration into reality?
- Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...
Quick links
Infographics
